Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VXFLL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
FGFR2/FGFR4 dual targeting antibody-drug conjugate
|
|||||
| Synonyms |
FGFR2/FGFR4 dual targeting antibody-drug conjugate (Novartis/MorphoSys)
Click to Show/Hide
|
|||||
| Organization |
Novartis Institutes for Biomedical Research, Inc.; Novartis AG; MorphoSys AG
|
|||||
| Drug Status |
Terminated
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Lung cancer [ICD11:2C25]
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Fibroblast growth factor receptor 2 (FGFR2); Fibroblast growth factor receptor 4 (FGFR4)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.